Perosphere is a specialty pharmaceutical company with internationally recognized drug delivery expertise.

Feature

The NEW ENGLAND JOURNAL of MEDICINE

Perosphere’s Anticoagulant Reversal Agent Clinical Trial Results Published in The New England Journal of Medicine

read more...

Latest News

15Nov2014 Perosphere Presents Data on Investigational Anticoagulant Reversal Agent PER977 at 2014 American Heart Association (AHA) Annual Scientific Sessions in Chicago
05Nov2014 Perosphere’s Anticoagulant Reversal Agent Clinical Trial Results Published in the New England Journal of Medicine
23Oct2014 Perosphere Pharmaceutical Manufacturing Ribbon-Cutting
06Oct2014 Perosphere and Daiichi Sankyo Enter into a Clinical Trial
Collaboration Agreement for Phase 3 Studies of PER977 to
Investigate Reversal of the Anticoagulant Activity of the
Investigational Factor Xa-Inhibitor Edoxaban
25Apr2013 Perosphere and Daiichi Sankyo Enter into a Clinical Trial Agreement to Evaluate the Efficacy and Safety of PER977 to Reverse the Anticoagulant Activity of the Investigational, Oral, Once-Daily Factor Xa Inhibitor Edoxaban
21Dec2012 Perosphere Advisory Board Chairman, Professor Robert Langer, Wins the National Medal of Technology

Presentations & Publications

Perosphere featured in nature

"a single intravenous
dose of PER977 ... restored blood clotting time to within 10% above baseline within 10 minutes of administration"

read more...